OncoCyte Long Term Debt vs Net Debt Analysis

OCX Stock

USD 2.74 0.09 3.40%

OncoCyte Corp financial indicator trend analysis is much more than just breaking down OncoCyte Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OncoCyte Corp is a good investment. Please check the relationship between OncoCyte Corp Long Term Debt and its Net Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Long Term Debt vs Net Debt

Long Term Debt vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OncoCyte Corp Long Term Debt account and Net Debt. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between OncoCyte Corp's Long Term Debt and Net Debt is -0.6. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Net Debt in the same time period over historical financial statements of OncoCyte Corp, assuming nothing else is changed. The correlation between historical values of OncoCyte Corp's Long Term Debt and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of OncoCyte Corp are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Long Term Debt i.e., OncoCyte Corp's Long Term Debt and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.6

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that OncoCyte Corp has held for over one year. Long-term debt appears on OncoCyte Corp balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on OncoCyte Corp balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from OncoCyte Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OncoCyte Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.At this time, OncoCyte Corp's Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 9.66 in 2024, whereas Selling General Administrative is likely to drop slightly above 11.5 M in 2024.

OncoCyte Corp fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets
Total Assets		0.41	0.83	0.89	0.95	0.91	-0.8	-0.75	0.98	0.86	0.99	0.08	0.85	0.77	0.68	-0.55	0.88	-0.32	0.98	0.91	0.88	-0.25	0.93	0.8	0.82	-0.71
Short Long Term Debt Total	0.41		-0.01	0.55	0.52	0.48	-0.06	-0.25	0.28	0.27	0.43	0.64	0.26	0.28	0.22	-0.24	0.57	0.07	0.32	0.48	0.27	0.47	0.28	0.3	0.41	-0.06
Other Current Liab	0.83	-0.01		0.78	0.69	0.78	-0.81	-0.72	0.86	0.78	0.81	-0.3	0.76	0.71	0.64	-0.55	0.6	-0.45	0.89	0.78	0.81	-0.43	0.87	0.74	0.67	-0.73
Total Current Liabilities	0.89	0.55	0.78		0.8	0.86	-0.57	-0.67	0.85	0.67	0.91	0.11	0.66	0.67	0.57	-0.44	0.8	-0.33	0.91	0.86	0.71	0.05	0.84	0.7	0.73	-0.75
Total Stockholder Equity	0.95	0.52	0.69	0.8		0.88	-0.82	-0.68	0.92	0.9	0.93	0.23	0.89	0.71	0.63	-0.59	0.92	-0.15	0.88	0.88	0.91	-0.28	0.84	0.74	0.79	-0.5
Property Plant And Equipment Net	0.91	0.48	0.78	0.86	0.88		-0.67	-0.81	0.82	0.75	0.91	0.0	0.72	0.81	0.73	-0.64	0.93	-0.46	0.88	1.0	0.78	-0.3	0.83	0.84	0.86	-0.53
Net Debt	-0.8	-0.06	-0.81	-0.57	-0.82	-0.67		0.54	-0.85	-0.98	-0.72	0.09	-0.97	-0.56	-0.5	0.62	-0.62	0.04	-0.74	-0.67	-0.96	0.55	-0.74	-0.6	-0.56	0.4
Retained Earnings	-0.75	-0.25	-0.72	-0.67	-0.68	-0.81	0.54		-0.68	-0.6	-0.77	0.35	-0.53	-1.0	-0.99	0.76	-0.74	0.72	-0.76	-0.81	-0.58	0.49	-0.88	-0.99	-0.97	0.58
Accounts Payable	0.98	0.28	0.86	0.85	0.92	0.82	-0.85	-0.68		0.88	0.95	0.03	0.89	0.7	0.61	-0.5	0.79	-0.25	0.97	0.82	0.91	-0.26	0.92	0.73	0.74	-0.75
Cash	0.86	0.27	0.78	0.67	0.9	0.75	-0.98	-0.6	0.88		0.79	0.04	0.99	0.63	0.55	-0.66	0.72	-0.05	0.79	0.75	0.99	-0.44	0.78	0.66	0.65	-0.4
Non Current Assets Total	0.99	0.43	0.81	0.91	0.93	0.91	-0.72	-0.77	0.95	0.79		0.08	0.78	0.78	0.7	-0.52	0.89	-0.37	0.98	0.91	0.82	-0.2	0.93	0.81	0.84	-0.75
Other Assets	0.08	0.64	-0.3	0.11	0.23	0.0	0.09	0.35	0.03	0.04	0.08		0.11	-0.3	-0.38	0.38	0.09	0.46	-0.01	0.0	0.08	0.59	-0.13	-0.28	-0.16	0.15
Cash And Short Term Investments	0.85	0.26	0.76	0.66	0.89	0.72	-0.97	-0.53	0.89	0.99	0.78	0.11		0.57	0.48	-0.55	0.68	-0.03	0.78	0.72	0.99	-0.38	0.77	0.6	0.59	-0.44
Common Stock Total Equity	0.77	0.28	0.71	0.67	0.71	0.81	-0.56	-1.0	0.7	0.63	0.78	-0.3	0.57		0.99	-0.76	0.76	-0.69	0.77	0.81	0.61	-0.48	0.9	1.0	0.98	-0.59
Common Stock Shares Outstanding	0.68	0.22	0.64	0.57	0.63	0.73	-0.5	-0.99	0.61	0.55	0.7	-0.38	0.48	0.99		-0.77	0.7	-0.7	0.68	0.73	0.52	-0.52	0.84	0.98	0.96	-0.53
Short Term Investments	-0.55	-0.24	-0.55	-0.44	-0.59	-0.64	0.62	0.76	-0.5	-0.66	-0.52	0.38	-0.55	-0.76	-0.77		-0.65	0.21	-0.5	-0.64	-0.56	0.6	-0.61	-0.77	-0.72	0.14
Other Current Assets	0.88	0.57	0.6	0.8	0.92	0.93	-0.62	-0.74	0.79	0.72	0.89	0.09	0.68	0.76	0.7	-0.65		-0.27	0.82	0.93	0.72	-0.28	0.77	0.79	0.85	-0.45
Other Stockholder Equity	-0.32	0.07	-0.45	-0.33	-0.15	-0.46	0.04	0.72	-0.25	-0.05	-0.37	0.46	-0.03	-0.69	-0.7	0.21	-0.27		-0.42	-0.46	-0.11	0.26	-0.52	-0.67	-0.63	0.52
Total Liab	0.98	0.32	0.89	0.91	0.88	0.88	-0.74	-0.76	0.97	0.79	0.98	-0.01	0.78	0.77	0.68	-0.5	0.82	-0.42		0.88	0.82	-0.21	0.94	0.79	0.8	-0.82
Property Plant And Equipment Gross	0.91	0.48	0.78	0.86	0.88	1.0	-0.67	-0.81	0.82	0.75	0.91	0.0	0.72	0.81	0.73	-0.64	0.93	-0.46	0.88		0.78	-0.3	0.83	0.84	0.86	-0.53
Total Current Assets	0.88	0.27	0.81	0.71	0.91	0.78	-0.96	-0.58	0.91	0.99	0.82	0.08	0.99	0.61	0.52	-0.56	0.72	-0.11	0.82	0.78		-0.39	0.8	0.65	0.64	-0.48
Short Term Debt	-0.25	0.47	-0.43	0.05	-0.28	-0.3	0.55	0.49	-0.26	-0.44	-0.2	0.59	-0.38	-0.48	-0.52	0.6	-0.28	0.26	-0.21	-0.3	-0.39		-0.34	-0.48	-0.4	0.02
Intangible Assets	0.93	0.28	0.87	0.84	0.84	0.83	-0.74	-0.88	0.92	0.78	0.93	-0.13	0.77	0.9	0.84	-0.61	0.77	-0.52	0.94	0.83	0.8	-0.34		0.91	0.9	-0.8
Common Stock	0.8	0.3	0.74	0.7	0.74	0.84	-0.6	-0.99	0.73	0.66	0.81	-0.28	0.6	1.0	0.98	-0.77	0.79	-0.67	0.79	0.84	0.65	-0.48	0.91		0.99	-0.6
Property Plant Equipment	0.82	0.41	0.67	0.73	0.79	0.86	-0.56	-0.97	0.74	0.65	0.84	-0.16	0.59	0.98	0.96	-0.72	0.85	-0.63	0.8	0.86	0.64	-0.4	0.9	0.99		-0.59
Net Tangible Assets	-0.71	-0.06	-0.73	-0.75	-0.5	-0.53	0.4	0.58	-0.75	-0.4	-0.75	0.15	-0.44	-0.59	-0.53	0.14	-0.45	0.52	-0.82	-0.53	-0.48	0.02	-0.8	-0.6	-0.59

Click cells to compare fundamentals

OncoCyte Corp Account Relationship Matchups

OncoCyte Corp fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.9M	55.4M	159.6M	100.1M	74.9M	49.1M
Short Long Term Debt Total	5.9M	8.6M	5.7M	3.5M	2.9M	4.1M
Other Current Liab	2.6M	600K	9.5M	10.0M	5.6M	4.4M
Total Current Liabilities	4.4M	9.0M	14.1M	12.1M	7.2M	7.6M
Total Stockholder Equity	30.8M	33.5M	65.2M	34.3M	25.6M	22.0M
Property Plant And Equipment Net	3.7M	6.5M	8.5M	10.9M	5.4M	3.8M
Net Debt	(16.1M)	1.5M	(29.9M)	(16.4M)	(6.6M)	(6.9M)
Retained Earnings	(93.7M)	(123.7M)	(187.8M)	(260.7M)	(289.9M)	(275.4M)
Accounts Payable	469K	432K	2.4M	1.3M	953K	684.9K
Cash	22.1M	7.1M	35.6M	20.0M	9.4M	12.8M
Non Current Assets Total	16.9M	46.2M	120.4M	74.6M	64.2M	33.5M
Other Assets	2.2M	2.1M	2.0M	1.0	1.15	1.09
Cash And Short Term Investments	22.5M	7.8M	36.5M	20.4M	9.4M	14.5M
Common Stock Total Equity	124.6M	157.2M	253.0M	294.9M	339.2M	356.1M
Common Stock Shares Outstanding	2.6M	3.3M	4.4M	5.5M	7.7M	8.0M
Short Term Investments	428K	379K	675K	904K	433K	0.0
Liabilities And Stockholders Equity	39.9M	55.4M	159.6M	100.1M	74.9M	49.1M
Other Current Assets	505K	1.2M	1.2M	977K	782K	592.1K
Other Stockholder Equity	948K	343K	37K	(5.3M)	(4.8M)	(4.5M)
Total Liab	9.0M	21.9M	94.3M	65.8M	49.3M	27.1M
Property Plant And Equipment Gross	3.7M	6.5M	8.5M	10.9M	5.4M	3.8M
Total Current Assets	23.0M	9.2M	39.1M	25.5M	10.7M	15.7M
Accumulated Other Comprehensive Income	(343K)	0.0	37K	39K	49K	51.5K
Short Term Debt	1.4M	2.8M	2.1M	815K	665K	631.8K
Common Stock	124.6M	157.2M	253.0M	294.9M	310.3M	325.8M
Property Plant Equipment	614K	3.7M	6.5M	8.5M	9.8M	10.3M
Net Tangible Assets	30.8M	9.3M	(44.7M)	(22.0M)	(19.8M)	(18.8M)
Long Term Debt	1.1M	347K	1.9M	1.5M	1.7M	905.1K
Non Currrent Assets Other	2.2M	1.9M	2.0M	2.1M	463K	439.9K
Retained Earnings Total Equity	(93.7M)	(123.7M)	(187.8M)	(260.7M)	(234.6M)	(222.9M)
Long Term Debt Total	1.4M	534K	2.0M	1.5M	1.7M	1.2M
Non Current Liabilities Total	4.6M	12.9M	80.2M	53.7M	42.1M	26.9M
Capital Lease Obligations	2.9M	4.7M	4.4M	3.5M	2.9M	2.8M
Net Invested Capital	33.9M	37.4M	66.5M	34.3M	20.5M	32.0M
Net Working Capital	18.5M	230K	25.0M	13.4M	3.5M	3.3M
Capital Stock	124.6M	157.2M	253.0M	294.9M	310.3M	222.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether OncoCyte Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OncoCyte Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncocyte Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncocyte Corp Stock:

How To Invest In OncoCyte

Details

Is OncoCyte Stock a good investment?

Details

What is OncoCyte Corp's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Note that the OncoCyte Corp information on this page should be used as a complementary analysis to other OncoCyte Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for OncoCyte Stock analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	CEOs Directory Screen CEOs from public companies around the world
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities

Is OncoCyte Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OncoCyte Corp. If investors know OncoCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OncoCyte Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.32)

Revenue Per Share

0.168

Quarterly Revenue Growth

(0.41)

Return On Assets

(0.18)

Return On Equity

(1.32)

The market value of OncoCyte Corp is measured differently than its book value, which is the value of OncoCyte that is recorded on the company's balance sheet. Investors also form their own opinion of OncoCyte Corp's value that differs from its market value or its book value, called intrinsic value, which is OncoCyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OncoCyte Corp's market value can be influenced by many factors that don't directly affect OncoCyte Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between OncoCyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if OncoCyte Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OncoCyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OncoCyte Long Term Debt vs Net Debt Analysis

Long Term Debt vs Net Debt

Long Term Debt vs Net Debt Correlation Analysis

Correlation Coefficient

Long Term Debt

Net Debt

OncoCyte Corp fundamental ratios Correlations

OncoCyte Corp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OncoCyte Corp fundamental ratios Accounts

Also Currently Popular

Complementary Tools for OncoCyte Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Common Stock Total Equity	- 1.0	Retained Earnings
Common Stock	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.99	Retained Earnings
Cash	- 0.98	Net Debt
Property Plant Equipment	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.97	Net Debt